Health economics substudy of PLATO shows BRILIQUE to be a cost effective treatment versus generic Clopidogrel
- Details
- Category: AstraZeneca
AstraZeneca announced new health economics data from a substudy of the PLATO trial showed that treating a broad spectrum of acute coronary syndrome (ACS) patients with BRILIQUE (ticagrelor) was more cost-effective than treatment with generic clopidogrel.
Sanofi-aventis and Medicines for Malaria Venture Join Forces to Develop Innovative Malaria Drugs
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Medicines for Malaria Venture (MMV) have signed an alliance agreement to research malaria treatments as well as the first research project agreement within the framework of the alliance.
Novartis gains FDA approval for Afinitor®
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease[4].
FDA approves linagliptin tablets for the treatment of type 2 diabetes
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.(1)
Pfizer Reports First-Quarter 2011 Results
- Details
- Category: Pfizer
First-quarter 2011 revenues were $16.5 billion, consistent with the year-ago quarter. Revenues for first-quarter 2011 compared with the year-ago quarter were favorably impacted by $97 million, or 1%, due to foreign exchange, and $224 million, or 1%, due to the addition of legacy King products.
Bayer off to a successful start to 2011
- Details
- Category: Bayer
Sales of the Bayer Group climbed by 13.2 percent in the first quarter of 2011, to EUR 9,415 million (Q1 2010: EUR 8,316 million). Adjusted for currency and portfolio effects, sales were up by 10.4 percent.
Pfizer Announces Top-Line Results of Final Two Pivotal Phase 3 Trials of Tofacitinib (CP-690,550)
- Details
- Category: Pfizer
Pfizer Inc. announced top-line results from the ORAL Standard (A3921064) and ORAL Step (A3921032) Phase 3 studies of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor.
More Pharma News ...
- Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval
- Genzyme Revenues Grow in First-Quarter 2011
- Shire delivers a strong first quarter performance
- Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
- Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005
- Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives
- Lundbeck's partner Mochida receives approval of Lexapro in Japan